As reported in the recently published phase 3 RCT DESTINY-Breast04, 52.3% of HER2-low advanced BC patients had an overall response, ranging from 9.0 to 11.3 months of progression-free survival [16]. The gene discussed is ERBB2; the disease is breast cancer.